Rikke Riisbro

589 total citations
17 papers, 480 citations indexed

About

Rikke Riisbro is a scholar working on Cancer Research, Hematology and Oncology. According to data from OpenAlex, Rikke Riisbro has authored 17 papers receiving a total of 480 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Cancer Research, 7 papers in Hematology and 5 papers in Oncology. Recurrent topics in Rikke Riisbro's work include Protease and Inhibitor Mechanisms (10 papers), Blood Coagulation and Thrombosis Mechanisms (7 papers) and Cell Adhesion Molecules Research (5 papers). Rikke Riisbro is often cited by papers focused on Protease and Inhibitor Mechanisms (10 papers), Blood Coagulation and Thrombosis Mechanisms (7 papers) and Cell Adhesion Molecules Research (5 papers). Rikke Riisbro collaborates with scholars based in Denmark, Sweden and Belgium. Rikke Riisbro's co-authors include Ib Jarle Christensen, Nils Brünner, Kenneth Smith, Adrian L. Harris, Michael J. Greenall, Nils Brünner, Ross W. Stephens, Estrid Høgdall, Claus Høgdall and Hans Jørgen Nielsen and has published in prestigious journals such as Blood, Molecular Cancer Therapeutics and Breast Cancer Research and Treatment.

In The Last Decade

Rikke Riisbro

17 papers receiving 472 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rikke Riisbro Denmark 11 216 204 189 107 91 17 480
JA Hamilton Australia 12 142 0.7× 163 0.8× 152 0.8× 112 1.0× 278 3.1× 21 567
C. Caenazzo Italy 10 234 1.1× 126 0.6× 194 1.0× 75 0.7× 58 0.6× 17 451
Mahmut Celiker United States 8 129 0.6× 118 0.6× 114 0.6× 60 0.6× 48 0.5× 12 336
Sabina Pierpaoli Italy 12 65 0.3× 230 1.1× 76 0.4× 188 1.8× 166 1.8× 14 505
Michele Wezeman United States 7 62 0.3× 272 1.3× 410 2.2× 319 3.0× 130 1.4× 9 691
B. Rovati Italy 16 96 0.4× 219 1.1× 318 1.7× 79 0.7× 265 2.9× 38 651
Farooq Siddiqui United States 10 55 0.3× 133 0.7× 50 0.3× 202 1.9× 108 1.2× 19 453
Yingzhe Yu China 9 84 0.4× 195 1.0× 189 1.0× 195 1.8× 215 2.4× 23 626
Miho Nara Japan 12 193 0.9× 276 1.4× 113 0.6× 144 1.3× 138 1.5× 31 613
Rong‐Miao Zhou China 19 231 1.1× 459 2.3× 294 1.6× 29 0.3× 147 1.6× 61 868

Countries citing papers authored by Rikke Riisbro

Since Specialization
Citations

This map shows the geographic impact of Rikke Riisbro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rikke Riisbro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rikke Riisbro more than expected).

Fields of papers citing papers by Rikke Riisbro

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rikke Riisbro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rikke Riisbro. The network helps show where Rikke Riisbro may publish in the future.

Co-authorship network of co-authors of Rikke Riisbro

This figure shows the co-authorship network connecting the top 25 collaborators of Rikke Riisbro. A scholar is included among the top collaborators of Rikke Riisbro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rikke Riisbro. Rikke Riisbro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
Riisbro, Rikke, Lena Winstedt, Steve Pakola, et al.. (2009). Abstract A3: A first-in-man, phase I, dose escalation study of TB-403, a monoclonal antibody directed against PlGF, in healthy male subjects. Molecular Cancer Therapeutics. 8(12_Supplement). A3–A3. 1 indexed citations
3.
Offersen, Birgitte Vrou, Jan Alsner, Karen Ege Olsen, et al.. (2008). A comparison among HER2,TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer. Acta Oncologica. 47(4). 618–632. 20 indexed citations
4.
Offersen, Birgitte Vrou, Rikke Riisbro, Ann Knoop, Nils Brünner, & Jens Overgaard. (2007). Lack of association between level of Plasminogen Activator Inhibitor-1 and estimates of tumor angiogenesis in early breast cancer. Acta Oncologica. 46(6). 782–791. 2 indexed citations
5.
Verhamme, Peter, Steve Pakola, Marc Jacquemin, et al.. (2007). Phase I Clinical Trial of a Novel, Long-Acting Antithrombotic Drug: A Human Monoclonal Antibody Partially Inhibiting FVIII Activity.. Blood. 110(11). 312–312. 1 indexed citations
6.
Høgdall, Estrid, Rikke Riisbro, Ib Jarle Christensen, et al.. (2006). Prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) in Danish patients with recurrent epithelial ovarian cancer (REOC). Apmis. 114(10). 675–681. 4 indexed citations
7.
Riisbro, Rikke, Ib Jarle Christensen, Hans Jørgen Nielsen, et al.. (2005). Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration. The International Journal of Biological Markers. 20(2). 93–102. 21 indexed citations
8.
Riisbro, Rikke, Ib Jarle Christensen, Hans Jørgen Nielsen, et al.. (2005). Preoperative Plasma Soluble Urokinase Plasminogen Activator Receptor as a Prognostic Marker in Rectal Cancer Patients. An Eortc-Receptor and Biomarker Group Collaboration. The International Journal of Biological Markers. 20(2). 93–102. 21 indexed citations
9.
Grebenchtchikov, Nicolaï, Teresa Maguire, Rikke Riisbro, et al.. (2005). Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.. PubMed. 14(1). 235–9. 23 indexed citations
10.
Riisbro, Rikke, Nils Brünner, Ib Jarle Christensen, & Hans Jørgen Nielsen. (2004). Soluble urokinase plasminogen activator receptor in blood transfusion components. Transfusion Medicine. 14(4). 305–312. 5 indexed citations
11.
12.
Jensen, Morten Krogh, Mads Holten-Andersen, Rikke Riisbro, et al.. (2003). Elevated plasma levels of TIMP‐1 correlate with plasma suPAR/uPA in patients with chronic myeloproliferative disorders. European Journal Of Haematology. 71(5). 377–384. 17 indexed citations
13.
Johansen, Julia S., Ib Jarle Christensen, Rikke Riisbro, et al.. (2003). High Serum YKL-40 Levels in Patients with Primary Breast Cancer is Related to Short Recurrence Free Survival. Breast Cancer Research and Treatment. 80(1). 15–21. 111 indexed citations
14.
Riisbro, Rikke, Ib Jarle Christensen, Timo Piironen, et al.. (2002). Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer.. PubMed. 8(5). 1132–41. 100 indexed citations
15.
Jensen, Morten Krogh, Rikke Riisbro, Peter de Nully Brown, Nils Brünner, & Hans Carl Hasselbalch. (2002). Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera. European Journal Of Haematology. 69(1). 43–49. 12 indexed citations
16.
Riisbro, Rikke, Ross W. Stephens, Nils Brünner, et al.. (2001). Soluble Urokinase Plasminogen Activator Receptor in Preoperatively Obtained Plasma from Patients with Gynecological Cancer or Benign Gynecological Diseases. Gynecologic Oncology. 82(3). 523–531. 32 indexed citations
17.
Riisbro, Rikke, Ib Jarle Christensen, Claus Høgdall, Nils Brünner, & Estrid Høgdall. (2001). Soluble Urokinase Plasminogen Activator Receptor Measurements: Influence of Sample Handling. The International Journal of Biological Markers. 16(4). 233–239. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by JA Hamilton Breakdown of academic impact, for papers by C. Caenazzo Breakdown of academic impact, for papers by Mahmut Celiker Breakdown of academic impact, for papers by Sabina Pierpaoli Breakdown of academic impact, for papers by Michele Wezeman Breakdown of academic impact, for papers by B. Rovati Breakdown of academic impact, for papers by Farooq Siddiqui Breakdown of academic impact, for papers by Yingzhe Yu Breakdown of academic impact, for papers by Miho Nara Breakdown of academic impact, for papers by Rong‐Miao Zhou
Rankless by CCL
2026